Filling the need for trusted information on national health issues…

Trending on kff Subsidies Marketplaces Enrollment

Private Sector Involvement

  • your selections
Clear Search

Filter Results

date

Tags

  • results
Fully Funding Global Fund, Continuing PPPs Will Help Defeat TB, HIV, Malaria

The WHO “projects that as many as two million people may develop drug-resistant strains of [tuberculosis (TB)] worldwide by 2015 — despite everyone’s efforts to achieve the 2015 Millennium Development Goals related to TB,” John Lechleiter, chair, president and CEO of Eli Lilly and Company and chair of the Pharmaceutical Research…

Public, Private Sectors Should Address Antibiotic Resistance After Latest CDC Warning

Noting CDC Director Tom Frieden on Monday released a report showing “two million people in the United States are sickened every year with antibiotic-resistant infections, with at least 23,000 dying as a result,” a Washington Post editorial states, “The global toll is certainly much higher.” The editorial asks, “What is being…

Cross-Sector Partnerships Essential To Reaching Health-Related Development Goals

The race to meet the health-related U.N. Millennium Development Goals (MDGs) and the post-2015 development agenda “requires new thinking and fresh commitments from across all sectors — including industry, governments, multilaterals, [non-governmental organizations (NGOs)], and other organizations — to cross-sector partnerships that drive systemwide change,” Eduardo Pisani, director general of…

U.N. Report Gives Mixed Review Of MDG 8 On Partnerships, Trade

“The international community must live up to the commitments it made in support of achieving universally accepted anti-poverty targets, [U.N.] Secretary-General Ban Ki-moon [on Thursday] said launching a new report [.pdf] which finds that despite significant successes, the global economic slowdown continues to hinder progress on the Millennium Development Goals…

FDA Approves GSK Antiretroviral Drug Dolutegravir

The FDA on Monday approved GlaxoSmithKline’s antiretroviral dolutegravir, an integrase strand transfer inhibitor “that was developed by ViiV Healthcare Ltd., its joint venture with two other drugmakers,” Bloomberg reports (Edney, 8/12). “The pill is taken daily in combination with others and can be prescribed to patients who have never taken…

Examining Need For Increased Investment Into Africa’s Pharmaceutical Production Industry

Writing in the Global Health Corps “Fellows” blog, fellow Brian Ngwatu from Uganda argues for increased investment in the local pharmaceutical production industry in Africa, which boasts “11 percent of the world’s population and 25 percent of the global disease burden” but “only one percent share of the world’s pharmaceutical…

PATH Working With Private Sector To Develop Public Health Innovations

The Atlantic speaks with Anurag Mairal, director of technology solutions at PATH Health Technologies, about PATH’s “wor[k] with the commercial sector to scale, distribute, and market its innovations.” Mairal’s “approach includes disruptive innovation (disrupt the global health system by changing the cost equation, moving away from a grants-based approach to…

Former Pharmaceutical Executive Speaks About Vaccine Development, Distribution

In partnership with the Skoll World Forum, Forbes features an interview with Kevin Reilly, former president of the vaccines and nutrition division of Wyeth Pharmaceuticals, who discusses the challenges of vaccine development and distribution. “Increasingly, I see pharmaceutical and vaccine manufacturers engaging in the dialogue about strengthening immunization and distribution…

Price Reduction Agreement For Cytomegalovirus Might Help Improve Screening, Awareness

The Center for Global Health Policy’s “Science Speaks” blog describes “an agreement [.pdf] announced this week between the Medicines Patent Pool and Roche, the maker of the oral drug valganciclovir, which treats cytomegalovirus retinitis,” an infection common among people living with HIV, particularly in Asian countries. “The agreement, signed in…